NCT05184842 · OUTCOME

Rate of Hospitalization

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML · Source last updated 2026-01-05

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 12 months

What was measured

Rate of hospitalization will be defined as any hospitalization for complication related to myeloid malignancy or treatment. Initial admission for diagnosis or initiation of therapy will not be considered an event. For purposes of this study the rate of hospitalization will be defined as a percentage of participants who meet these criteria.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Rate of hospitalization will be defined as any hospitalization for complication related to myeloid malignancy or treatment. Initial admission for diagnosis or initiation of therapy will not be considered an event. For purposes of this study the rate of hospitalization will be defined as a percentage of participants who meet these criteria.
reporting Status: NOT_POSTED
time Frame: Up to 12 months
title: Rate of Hospitalization
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice